OpenURL Connection Search

Select item for more details and to access through your institution.

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
Published in:
JNCI Cancer Spectrum, 2022, v. 6, n. 4, p. 1, doi. 10.1093/jncics/pkac043
By:
- James, Nicholas D;
- Ingleby, Fiona C;
- Clarke, Noel W;
- Amos, Claire L;
- Attard, Gerhardt;
- Brawley, Christopher D;
- Chowdhury, Simon;
- Cross, William;
- Dearnaley, David P;
- Gilbert, Duncan C;
- Gillessen, Silke;
- Jones, Robert J;
- Langley, Ruth E;
- Macnair, Archie;
- Malik, Zafar I;
- Mason, Malcolm D;
- Matheson, David J;
- Millman, Robin;
- Parker, Chris C;
- Rush, Hannah L
Publication type:
Article
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476).
Published in:
International Journal of Cancer, 2022, v. 151, n. 3, p. 422, doi. 10.1002/ijc.34018
By:
- James, Nicholas D.;
- Clarke, Noel W.;
- Cook, Adrian;
- Ali, Adnan;
- Hoyle, Alex P.;
- Attard, Gerhardt;
- Brawley, Christopher D.;
- Chowdhury, Simon;
- Cross, William R.;
- Dearnaley, David P.;
- de Bono, Johann S.;
- Diaz‐Montana, Carlos;
- Gilbert, Duncan;
- Gillessen, Silke;
- Gilson, Clare;
- Jones, Rob J.;
- Langley, Ruth E.;
- Malik, Zafar I.;
- Matheson, David J.;
- Millman, Robin
Publication type:
Article
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Published in:
PLoS Medicine, 2022, v. 19, n. 6, p. 1, doi. 10.1371/journal.pmed.1003998
By:
- Parker, Chris C.;
- James, Nicholas D.;
- Brawley, Christopher D.;
- Clarke, Noel W.;
- Ali, Adnan;
- Amos, Claire L.;
- Attard, Gerhardt;
- Chowdhury, Simon;
- Cook, Adrian;
- Cross, William;
- Dearnaley, David P.;
- Douis, Hassan;
- Gilbert, Duncan C.;
- Gilson, Clare;
- Gillessen, Silke;
- Hoyle, Alex;
- Jones, Rob J.;
- Langley, Ruth E.;
- Malik, Zafar I.;
- Mason, Malcolm D.
Publication type:
Article
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Published in:
2022
By:
- Parker, Chris C;
- James, Nicholas D;
- Brawley, Christopher D;
- Clarke, Noel W;
- Ali, Adnan;
- Amos, Claire L;
- Attard, Gerhardt;
- Chowdhury, Simon;
- Cook, Adrian;
- Cross, William;
- Dearnaley, David P;
- Douis, Hassan;
- Gilbert, Duncan C;
- Gilson, Clare;
- Gillessen, Silke;
- Hoyle, Alex;
- Jones, Rob J;
- Langley, Ruth E;
- Malik, Zafar I;
- Mason, Malcolm D
Publication type:
journal article
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
Published in:
PLoS ONE, 2022, v. 17, n. 6, p. 1, doi. 10.1371/journal.pone.0269192
By:
- Clarke, Caroline S.;
- Hunter, Rachael M.;
- Gabrio, Andrea;
- Brawley, Christopher D.;
- Ingleby, Fiona C.;
- Dearnaley, David P.;
- Matheson, David;
- Attard, Gerhardt;
- Rush, Hannah L.;
- Jones, Rob J.;
- Cross, William;
- Parker, Chris;
- Russell, J. Martin;
- Millman, Robin;
- Gillessen, Silke;
- Malik, Zafar;
- Lester, Jason F.;
- Wylie, James;
- Clarke, Noel W.;
- Parmar, Mahesh K. B.
Publication type:
Article

Found: 5

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476).

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.